» Articles » PMID: 36451272

Modeling the Impact of Data Sharing on Variant Classification

Overview
Date 2022 Dec 1
PMID 36451272
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Many genetic variants are classified, but many more are variants of uncertain significance (VUS). Clinical observations of patients and their families may provide sufficient evidence to classify VUS. Understanding how long it takes to accumulate sufficient patient data to classify VUS can inform decisions in data sharing, disease management, and functional assay development.

Materials And Methods: Our software models the accumulation of clinical evidence (and excludes all other types of evidence) to measure their unique impact on variant interpretation. We illustrate the time and probability for VUS classification when laboratories share evidence, when they silo evidence, and when they share only variant interpretations.

Results: Using conservative assumptions for frequencies of observed clinical evidence, our models show the probability of classifying rare pathogenic variants with an allele frequency of 1/100 000 increases from less than 25% with no data sharing to nearly 80% after one year when labs share data, with nearly 100% classification after 5 years. Conversely, our models found that extremely rare (1/1 000 000) variants have a low probability of classification using only clinical data.

Discussion: These results quantify the utility of data sharing and demonstrate the importance of alternative lines of evidence for interpreting rare variants. Understanding variant classification circumstances and timelines provides valuable insight for data owners, patients, and service providers. While our modeling parameters are based on our own assumptions of the rate of accumulation of clinical observations, users may download the software and run simulations with updated parameters.

Conclusions: The modeling software is available at https://github.com/BRCAChallenge/classification-timelines.

Citing Articles

Using metabolic abnormalities of carriers in the neonatal period to evaluate the pathogenicity of variants of uncertain significance in methylmalonic acidemia.

Xiao D, Shi C, Zhang Y, Li S, Ye Y, Yuan G Front Genet. 2024; 15:1403913.

PMID: 39076170 PMC: 11284102. DOI: 10.3389/fgene.2024.1403913.


Functional assay for assessment of pathogenicity of BAP1 variants.

Repo P, Backlund M, Kivela T, Turunen J Hum Mol Genet. 2023; 33(5):426-434.

PMID: 37956408 PMC: 10877462. DOI: 10.1093/hmg/ddad193.


Combining clinical and molecular characterization of CDH1: a multidisciplinary approach to reclassification of a splicing variant.

Fillman C, Anantharajah A, Marmelstein B, Dillon M, Horton C, Peterson C Fam Cancer. 2023; 22(4):521-526.

PMID: 37540482 DOI: 10.1007/s10689-023-00346-z.

References
1.
Rebbeck T, Friebel T, Lynch H, Neuhausen S, van t Veer L, Garber J . Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004; 22(6):1055-62. DOI: 10.1200/JCO.2004.04.188. View

2.
Hampel H, Pearlman R, Beightol M, Zhao W, Jones D, Frankel W . Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer. JAMA Oncol. 2018; 4(6):806-813. PMC: 5885168. DOI: 10.1001/jamaoncol.2018.0104. View

3.
Wexler R, Elton T, Pleister A, Feldman D . Cardiomyopathy: an overview. Am Fam Physician. 2010; 79(9):778-84. PMC: 2999879. View

4.
Tavtigian S, Greenblatt M, Harrison S, Nussbaum R, Prabhu S, Boucher K . Modeling the ACMG/AMP variant classification guidelines as a Bayesian classification framework. Genet Med. 2018; 20(9):1054-1060. PMC: 6336098. DOI: 10.1038/gim.2017.210. View

5.
Shirts B, Jacobson A, Jarvik G, Browning B . Large numbers of individuals are required to classify and define risk for rare variants in known cancer risk genes. Genet Med. 2013; 16(7):529-34. PMC: 4063879. DOI: 10.1038/gim.2013.187. View